PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results on two of the RNA interference (RNAi) based therapies in its cardiometabolic pipeline at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago. The presentations included multiple studies of plozasiran in patients with familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (sHTG), and interim results from a Phase 1/2a study of investigational ARO-DIMER-PA